KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Gross Margin (2018 - 2025)

Rigel Pharmaceuticals (RIGL) has 8 years of Gross Margin data on record, last reported at 91.47% in Q4 2025.

  • For Q4 2025, Gross Margin rose 152.0% year-over-year to 91.47%; the TTM value through Dec 2025 reached 93.33%, up 373.0%, while the annual FY2025 figure was 93.33%, 373.0% up from the prior year.
  • Gross Margin reached 91.47% in Q4 2025 per RIGL's latest filing, down from 93.16% in the prior quarter.
  • Across five years, Gross Margin topped out at 99.61% in Q1 2021 and bottomed at 85.49% in Q3 2024.
  • Average Gross Margin over 5 years is 95.01%, with a median of 95.79% recorded in 2025.
  • Peak YoY movement for Gross Margin: tumbled -1000bps in 2024, then surged 767bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 97.61% in 2021, then increased by 2bps to 99.33% in 2022, then decreased by -10bps to 89.41% in 2023, then rose by 1bps to 89.95% in 2024, then grew by 2bps to 91.47% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 91.47% in Q4 2025, 93.16% in Q3 2025, and 95.57% in Q2 2025.